-
FDA Advisory Panel Recommends Easing Regulations for Certain Peptides
An FDA advisory panel has recommended loosening regulatory restrictions on select peptides, responding to growing public and scientific interest in this category of compounds.
-
FDA Peptide Review Could Expand Access Through Compounding Pharmacies
A new FDA review of peptide compounds may open the door for compounding pharmacies to prepare more peptide-based therapies, potentially widening patient access to these treatments.
-
FDA Advisory Committee Backs Continued Access to Compounded Peptides
An FDA advisory committee voted in favor of preserving access to certain compounded peptides, a notable win for patients and practitioners who rely on these therapies.
-

FDA Advisory Panel Narrowly Endorses Several Peptides Linked to RFK Jr.’s Health Agenda
An FDA advisory committee voted narrowly in favor of several peptide compounds that have drawn public attention from Health and Human Services Secretary Robert F. Kennedy Jr., though the panel’s recommendation is nonbinding and final approval decisions remain with the agency.
-

HHS Signals Shift Toward Easing Restrictions on Psychedelic Research
Reporting indicates that Health and Human Services Secretary Robert F. Kennedy Jr. is following through on pledges to reduce regulatory barriers that have long limited research into psychedelic compounds. The developments could reshape how these substances are studied and potentially used in clinical settings.
-

Experimental Peptide Shows Early Promise in Spinal Cord Nerve Repair Trial
A peptide-based therapy being tested in a clinical trial has reportedly shown signs of nerve repair in patients with spinal cord injuries, according to a recent industry report. Researchers caution that results remain early-stage and require further validation.
-

FDA Advisory Panel Signals Support for Wider Legal Access to Popular Peptides
An FDA advisory committee has recommended expanding legitimate access to several peptide compounds that have circulated widely in unregulated online markets, potentially reshaping how these substances reach consumers.
-

FDA Advisory Panel Backs Wider Access to Six Popular Peptides
An FDA advisory panel has recommended loosening restrictions on six of seven widely discussed peptides, a move that could reshape how these compounds are regulated and accessed in the United States.
-

FDA Advisory Panel Narrowly Backs Adding Six Peptides to Compounding List
An FDA advisory committee voted by a narrow margin to recommend adding six peptide substances to a list eligible for pharmacy compounding, setting up further agency review before any final decision.
-

Report Projects Continued Growth for Global Peptide Therapeutics Market Through 2035
A new market research report forecasts sustained expansion of the global peptide therapeutics industry over the next decade, pointing to rising research investment and drug development activity. The projection reflects broader trends in the sector rather than a specific scientific breakthrough.